rs12551256 — IL33 IL33 protective asthma variant

IL-33 Alarmin Variant — The Intronic Brake on Type 2 Airway Inflammation

Interleukin-33¹¹ Interleukin-33
IL-33 is an alarmin cytokine constitutively expressed in the nuclei of airway epithelial and endothelial cells; when tissue is damaged by allergens, viruses, or mechanical stress, IL-33 is passively released from ruptured cells and triggers immediate type 2 immune activation sits at the very top of the type 2 inflammatory cascade that drives asthma, allergic rhinitis, and atopic sensitization. The IL33 gene on chromosome 9p24.1 is one of the most replicated asthma susceptibility loci in human genetics, and variants at this locus reliably associate with altered IL-33 expression levels in bronchial epithelium, plasma IL-33 protein concentration, and lifetime asthma risk. rs12551256 is an intronic variant within IL33 at GRCh38 chr9:6,231,239. The G allele was negatively associated with asthma in a 1,223-person Brazilian cohort (OR 0.71, P=0.017), suggesting it may sit within or near a regulatory element that modulates IL-33 expression or splicing efficiency.

The Mechanism

After tissue damage, IL-33 is released from the nucleus and binds its receptor complex ST2/IL-1RAcP on mast cells, basophils, and group 2 innate lymphoid cells²² group 2 innate lymphoid cells
ILC2s are innate immune cells that respond to epithelial alarmins (IL-33, IL-25, TSLP) without requiring antigen presentation; they are the dominant early source of IL-5 and IL-13 that drives eosinophilic airway inflammation. Binding activates MyD88→TRAF6→NF-κB and MAPK cascades, causing ILC2s and mast cells to flood the airway with IL-5 (driving eosinophilia), IL-13 (driving mucus and bronchospasm), and IL-9 (driving further mast cell activation). Environmental allergen proteases amplify this loop by cleaving full-length IL-33 into shorter, hyper-potent active forms. Variants that reduce IL-33 output from epithelial cells — whether through altered splicing efficiency, disrupted enhancer elements, or other intronic regulatory effects — blunt this entire cascade upstream of every cytokine downstream of IL-33.

The fine-mapping study at the IL33 locus³³ fine-mapping study at the IL33 locus
Aneas et al. Nature Communications 2021; identified a 5 kb enhancer-blocking element within the GWAS-defined 41 kb LD block that loops to the IL33 promoter; risk alleles rs1888909-T and rs992969-A increase bronchial epithelial IL33 mRNA and plasma IL-33 protein established that the IL33 asthma locus is an expression quantitative trait locus (eQTL) in airway epithelium, not in bulk lung tissue — meaning that the locus specifically tunes how much IL-33 is produced in the epithelial cells most exposed to inhaled triggers. rs12551256 at chr9:6,231,239 lies within the gene body of IL33, approximately 16 kb downstream of rs992969, and may mark an independent or correlated regulatory element within this same eQTL region.

The Evidence

The primary evidence for rs12551256 comes from a Brazilian case-control study⁴⁴ Brazilian case-control study
Queiroz et al., Int J Immunogenet 2017; 1,223 subjects genotyped on Illumina 2.5 Human Omni BeadChip; analyses adjusted for sex, age, helminth infection, and ancestry markers in a mixed European/African admixed population. The G allele was negatively associated with asthma (OR 0.71, 95% CI 0.53–0.94, P=0.017), a ~29% reduction in odds in heterozygotes and a larger expected reduction in GG homozygotes under an additive model. The effect size is modest and has not yet been independently replicated for this specific rsid in other cohorts — hence an evidence level of emerging.

The biological plausibility of a protective intronic variant at the IL33 locus is strongly supported by parallel human genetic evidence. The rare IL33 splice acceptor variant rs146597587-C⁵⁵ rare IL33 splice acceptor variant rs146597587-C
Zhu et al. PLoS Genet 2017; 103,104 participants for eosinophil analysis; 6,465 asthma cases vs 302,977 controls; rs146597587-C heterozygotes have ~40% lower total IL33 mRNA and a strongly protective effect on asthma risk (OR 0.47) and blood eosinophil counts (β=-0.21 SD, P=2.5×10⁻¹⁶) shows that even partial reduction in IL-33 availability provides robust protection against asthma. The clinical importance of the IL-33 pathway is confirmed by a phase 2 trial of itepekimab⁶⁶ a phase 2 trial of itepekimab
Wechsler et al. NEJM 2021; itepekimab (anti-IL-33 mAb, 300 mg SC every 2 weeks) vs placebo in moderate-to-severe asthma; loss-of-control events 22% vs 41%, OR 0.42, P=0.02, an anti-IL-33 monoclonal antibody, which achieved a 46% relative reduction in asthma loss-of-control events.

Practical Implications

Carriers of the G allele may have modestly lower IL-33 signalling capacity in their airway epithelium, which could translate to lower type 2 airway inflammation burden over a lifetime of allergen exposure. For carriers of AA (no G copies), the absence of this potential dampening variant — combined with other IL33 risk alleles at nearby positions — is a signal for proactive airway management. Practical steps include monitoring expiratory flow before symptoms develop and identifying specific aeroallergen triggers that activate airway epithelial IL-33 release (house dust mite proteases, cockroach allergens, tobacco smoke).

Interactions

rs12551256 lies within the IL33 gene body, approximately 16 kb downstream of the main asthma GWAS signal rs992969 and in the same genomic region as the cluster of IL33 eQTL variants. The degree of linkage disequilibrium between rs12551256 and nearby risk variants (rs992969, rs1888909) is not fully defined, particularly in non-European populations. In the Brazilian study population, LD patterns reflect the admixed European/African ancestry structure of the cohort.

rs146597587 (IL33 splice acceptor LOF variant) and rs992969 (IL33 upstream regulatory variant increasing IL33 expression) are the best-characterized IL33 variants in the platform. Carriers of rs12551256-GG with concurrent rs992969-GG (low-risk configuration at both loci) would represent the IL33 haplotype with the most consistent evidence for dampened IL-33-driven airway inflammation.

The receptor-side variant rs1420101 (IL1RL1/ST2) shapes how cells respond to whatever IL-33 is secreted — individuals with rs12551256-G (lower IL-33 production) and rs1420101 variants affecting sST2 decoy receptor levels have a dual dampening effect on the IL-33 → ST2 signalling axis.